Cutler Group’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-745
| Closed | -$136K | – | 7204 |
|
|
2021
Q2 | $136K | Sell |
745
-105
| -12% | -$18K | 0.01% | 1616 |
|
|
2021
Q1 | $129K | Sell |
850
-5,700
| -87% | -$882K | 0.01% | 1586 |
|
|
2020
Q4 | $1.02M | Buy |
6,550
+3,450
| +111% | +$443K | 0.08% | 387 |
|
|
2020
Q3 | $354K | Buy |
3,100
+2,300
| +288% | +$248K | 0.04% | 655 |
|
|
2020
Q2 | $89K | Sell |
800
-2,300
| -74% | -$244K | 0.01% | 1378 |
|
|
2020
Q1 | $278K | Buy |
3,100
+500
| +19% | +$49.1K | 0.03% | 791 |
|
|
2019
Q4 | $281K | Buy |
2,600
+1,200
| +86% | +$128K | 0.02% | 671 |
|
|
2019
Q3 | $137K | Buy |
1,400
+600
| +75% | +$67.6K | 0.02% | 897 |
|
|
2019
Q2 | $104K | Buy |
800
+700
| +700% | +$90.2K | 0.01% | 1080 |
|
|
2019
Q1 | $13K | Sell |
100
-1,399
| -93% | -$174K | ﹤0.01% | 2353 |
|
|
2018
Q4 | $145K | Buy |
1,499
+392
| +35% | +$46.3K | 0.02% | 812 |
|
|
2018
Q3 | $153K | Sell |
1,107
-4,003
| -78% | -$502K | 0.01% | 967 |
|
|
2018
Q2 | $634K | Buy |
5,110
+861
| +20% | +$101K | 0.07% | 372 |
|
|
2018
Q1 | $473K | Sell |
4,249
-13,051
| -75% | -$1.56M | 0.05% | 437 |
|
|
2017
Q4 | $2.07M | Sell |
17,300
-6,758
| -28% | -$823K | 0.11% | 167 |
|
|
2017
Q3 | $3.38M | Sell |
24,058
-65,177
| -73% | -$8.85M | 0.16% | 123 |
|
|
2017
Q2 | $10.9M | Buy |
89,235
+48,763
| +120% | +$5.68M | 0.51% | 38 |
|
|
2017
Q1 | $4.91M | Buy |
40,472
+10,652
| +36% | +$1.37M | 0.26% | 88 |
|
|
2016
Q4 | $3.65M | Buy |
29,820
+12,220
| +69% | +$1.5M | 0.17% | 117 |
|
|
2016
Q3 | $2.16M | Buy |
17,600
+5,400
| +44% | +$695K | 0.13% | 149 |
|
|
2016
Q2 | $1.42M | Buy |
12,200
+12,000
| +6,000% | +$1.7M | 0.1% | 205 |
|
|
2016
Q1 | $27K | Sell |
200
-395
| -66% | -$58K | ﹤0.01% | 2982 |
|
|
2015
Q4 | $113K | Buy |
+595
| New | +$104K | 0.01% | 1648 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM